Promising early data for Tonghua Dongbao’s obesity program

Early data from China-based Tonghua Dongbao Pharmaceutical Co. Ltd. (Shanghai:600867) suggest its dual GLP-1/GIP agonist could prove competitive in the obesity arena — and could open an opportunity for a global deal using the NewCo Model.

Tonghua Dongbao reported Tuesday that its molecule, THDBH120, led to weight loss of up to 9.36% at six weeks in a Phase Ib study. Three dosing regimens that involved increasing doses every two or four weeks all showed significance against placebo. The two lower-dosed regimens led to weight loss of 7.38% after four weeks, and 8.03% after six. The company didn’t report weight loss percentages for patients in the placebo arm...